{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:53:25Z","timestamp":1791143605730,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"BMFTR Bonn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eururo.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:32:23Z","timestamp":1791055943000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Accumulating Evidence Supports NECTIN4 as a Predictive Biomarker for Enfortumab Vedotin: The Compartment Still Matters"],"prefix":"10.1016","author":[{"given":"Niklas","family":"Kl\u00fcmper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Aggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.09.008_b0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa2601486","article-title":"Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer","volume":"395","author":"Galsky","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.008_b0010","doi-asserted-by":"crossref","first-page":"S1137","DOI":"10.1016\/j.annonc.2024.08.2051","article-title":"1966MO EV-302: exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.09.008_b0015","unstructured":"Cho BA, Perry CJ, Yoo S-K, et al. Pretreatment tumor NECTIN4 RNA expression is associated with first-line enfortumab vedotin plus pembrolizumab efficacy in metastatic urothelial cancer. Eur Urol in press n.d."},{"key":"10.1016\/j.eururo.2026.09.008_b0020","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN\u20104\/NECTIN\u20104 with molecular subtypes, PD\u2010L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2026.09.008_b0025","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.09.008_b0030","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.09.008_b0035","unstructured":"European Medicines Agency. Padcev (enfortumab vedotin): assessment report. Procedure No. EMEA\/H\/C\/005392\/0000. February 24, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/padcev-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.eururo.2026.09.008_b0040","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2026.44.7_suppl.854","article-title":"Membranous nectin-4 expression to predict enfortumab vedotin response in metastatic urothelial carcinoma","volume":"44","author":"Kl\u00fcmper","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.09.008_b0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1200\/JCO.2026.44.7_suppl.801","article-title":"Membranous and cytoplasmic nectin4 expression and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma","volume":"44","author":"Sternschuss","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.09.008_b0050","article-title":"Nectin-4 positivity in genitourinary malignancies: a systematic review","volume":"8","author":"Crupi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2026.09.008_b9001","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-26-0093","article-title":"Integrating NECTIN4 Amplification with Membranous NECTIN4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma","author":"Kl\u00fcmper","year":"2026","journal-title":"Clin Cancer Res"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602381X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602381X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:01:05Z","timestamp":1791140465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382602381X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":11,"alternative-id":["S030228382602381X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.008","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accumulating Evidence Supports NECTIN4 as a Predictive Biomarker for Enfortumab Vedotin: The Compartment Still Matters","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}